Imeik Technology Development Co (300896) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥1.66 billion, up 13.53% year-over-year; net profit attributable to shareholders was ¥1.12 billion, up 16.35% year-over-year.

• Both core product lines—solution and gel injectable fillers—achieved double-digit sales growth; solution products up 11.65%, gel products up 14.57% year-over-year.

• R&D investment increased 20.59% year-over-year, with 33 patent applications and 9 authorizations.

• The company expanded its product matrix by acquiring a controlling stake in Aimeichuang Medical Technology (Zhuhai), enhancing its presence in medical aesthetics equipment.

• Major construction project in Beijing progressing as planned, aiming to expand production capacity and support new product launches.

Financial highlights

• Operating income: ¥1.66 billion, up 13.53% year-over-year.

• Net profit attributable to shareholders: ¥1.12 billion, up 16.35% year-over-year.

• Operating cash flow: ¥1.15 billion, up 17.76% year-over-year.

• Basic and diluted EPS: ¥3.72, down from ¥4.45 due to a capital increase (stock split); ROE increased to 16.62%.

• Total assets at period end: ¥7.47 billion, up 8.96% from year-end 2023.

Outlook and guidance

• The company expects China's medical aesthetics market to maintain 10–15% annual growth in the coming years, driven by higher penetration and diversified demand.

• Ongoing R&D and new product launches, including botulinum toxin and weight management drugs, are expected to support future growth.

• The Beijing industrialization project will further expand capacity and product offerings upon completion.